MEI Pharma, Inc., a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. It also has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-369-7100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.62 million
Profitability
Miscellaneous
Employees32
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions
What is MEI Pharma's stock symbol?
MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."
How were MEI Pharma's earnings last quarter?
MEI Pharma Inc (NASDAQ:MEIP) issued its earnings results on Thursday, February, 7th. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.01. The business earned $2.05 million during the quarter, compared to analyst estimates of $3.05 million. MEI Pharma had a negative return on equity of 77.29% and a negative net margin of 1,454.51%. View MEI Pharma's Earnings History.
When is MEI Pharma's next earnings date?
What price target have analysts set for MEIP?
6 brokerages have issued 1-year price targets for MEI Pharma's shares. Their forecasts range from $7.00 to $12.00. On average, they anticipate MEI Pharma's stock price to reach $9.6667 in the next twelve months. This suggests a possible upside of 231.1% from the stock's current price. View Analyst Price Targets for MEI Pharma.
What is the consensus analysts' recommendation for MEI Pharma?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MEI Pharma.
Has MEI Pharma been receiving favorable news coverage?
News headlines about MEIP stock have trended positive on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MEI Pharma earned a coverage optimism score of 2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the near term.
Who are some of MEI Pharma's key competitors?
Some companies that are related to MEI Pharma include ANI Pharmaceuticals (ANIP), Akebia Therapeutics (AKBA), CannTrust (CTST), CannTrust (CNTTF), Athenex (ATNX), Rocket Pharmaceuticals (RCKT), Arvinas (ARVN), CymaBay Therapeutics (CBAY), TG Therapeutics (TGTX), Cara Therapeutics (CARA), ChemoCentryx (CCXI), Intra-Cellular Therapies (ITCI), Principia Biopharma (PRNB), ArQule (ARQL) and Vital Therapies (VTL).
What other stocks do shareholders of MEI Pharma own?
Who are MEI Pharma's key executives?
MEI Pharma's management team includes the folowing people:
- Dr. Daniel P. Gold, CEO, Pres & Director (Age 65)
- Mr. Brian G. Drazba CPA, Sec. & CFO (Age 58)
- Mr. David M. Urso Esq., J.D., COO, Sr. VP of Corp. Devel. & Gen. Counsel (Age 55)
- Dr. Robert D. Mass M.D., Chief Medical Officer (Age 65)
- Mr. David A. Walsey, VP of IR & Corp. Communications
Who are MEI Pharma's major shareholders?
MEI Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Tibra Equities Europe Ltd (0.21%). Company insiders that own MEI Pharma stock include Charles V Baltic III and David M Urso. View Institutional Ownership Trends for MEI Pharma.
Which institutional investors are buying MEI Pharma stock?
How do I buy shares of MEI Pharma?
Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEI Pharma's stock price today?
One share of MEIP stock can currently be purchased for approximately $2.92.
How big of a company is MEI Pharma?
MEI Pharma has a market capitalization of $207.76 million and generates $1.62 million in revenue each year. The company earns $-40,060,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. MEI Pharma employs 32 workers across the globe.
What is MEI Pharma's official website?
How can I contact MEI Pharma?
MEI Pharma's mailing address is 3611 VALLEY CENTRE DRIVE SUITE 500, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]
MarketBeat Community Rating for MEI Pharma (NASDAQ MEIP)
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe MEIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
